Clinical · Molecular biology
Coexisting driver alterations in non-small cell lung cancer: Prevalence, clonal architecture, and impact on survival and progression
Summary
A study involving 5420 non-small cell lung cancer (NSCLC) cases investigated the prevalence and impact of coexisting driver genetic alterations. Coexisting mutations were found in 3.9% of tumors, more frequently in females, with KRAS and PIK3CA being the most common combination. Clonality analysis revealed KRAS and EGFR as initiating drivers, while PIK3CA, AKT1, and IDH1 were mostly secondary events. The presence of EGFR + KRAS mutations was significantly associated with worse overall survival in both early and advanced stages. These findings emphasize the importance of comprehensive genomic profiling for effective therapeutic management.
Critical appraisal
Clinical. This large-scale retrospective study (5420 cases) highlights the critical need for comprehensive genomic profiling to identify coexisting driver alterations in NSCLC. The co-occurrence of EGFR and KRAS mutations serves as a clear negative prognostic biomarker, associated with significantly worse overall survival compared to single mutations (HR ranging from 2.58 to 4.14 depending on stage and comparison). These findings warrant clinical trials exploring specific therapeutic strategies for these patient subgroups, potentially involving combinations of EGFR and KRAS inhibitors or other pathway targets. The time to clinical impact could be 3-5 years, guiding more personalized treatment decisions.
Molecular biology. The discovery of the prevalence (3.9%) and clonal architecture of coexisting driver mutations is crucial. Identifying KRAS and EGFR as initiating events, and PIK3CA, AKT1, IDH1 as secondary events, provides mechanistic insights into tumor progression. This understanding of clonal hierarchy could guide the development of therapies targeting specific pathways at different stages of tumor evolution. Genomic profiling, likely based on NGS panels, is the underlying technology enabling these discoveries, underscoring its essential role in molecular tumor characterization.
The summary and the appraisal were written by a language model from the title and abstract of the original article. A curator decided to publish it. Methodology